Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 19/20 | 0.54 |
| ▸ | HTR2B | P41595 | 14/20 | 0.54 |
| ▸ | HTR2A | P28223 | 9/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6425272 | 0.98 | HTR2C (0.52) | HTR2CHTR2BHTR2ADRD2 | |
| SCHEMBL2018190 | 0.85 | HTR2C (0.58) | HTR2CHTR2BHTR2A | |
| SCHEMBL693081 | 0.85 | HTR2C (0.58) | HTR2CHTR2BHTR2A | |
| SCHEMBL692326 | 0.85 | HTR2C (0.58) | HTR2CHTR2BHTR2A | |
| SCHEMBL11558985 | 0.84 | SMN1; SMN2 (0.39) | HTR2CHTR2BHTR2A | |
| SCHEMBL23913128 | 0.80 | HTR2C (0.49) | HTR2CHTR2BHTR2A | |
| SCHEMBL22459930 | 0.80 | HTR2C (0.42) | HTR2CHTR2BHTR2A | |
| SCHEMBL21469131 | 0.80 | HTR2C (0.42) | HTR2CHTR2BHTR2A | |
| SCHEMBL22652086 | 0.80 | HTR2C (0.42) | HTR2CHTR2BHTR2A | |
| SCHEMBL8857971 | 0.80 | HTR2C (0.57) | HTR2CHTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765829-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS MGLUR1 ANTAGONISTS | SCHERING CORPORATION (US) | 2007-03-28 | — | — | EP | claimed |
| WO-2006002051-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS MGLUR1 ANTAGONISTS | SCHERING CORPORATION (US) | 2006-01-05 | — | — | WO | claimed |
| WO-1994020497-A1 | PYRROLO-PYRIDINE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1994-09-15 | — | — | WO | claimed |
| EP-3553064-B1 | COMPOUND CONTAINING TRICYCLIC HETEROARYL GROUP | HANGZHOU INNOGATE PHARMA CO LTD (CN) | 2023-06-07 | — | — | EP | disclosed |
| WO-2023088406-A1 | FUSED IMIDE DERIVATIVE | 正大天晴药业集团股份有限公司 | 2023-05-25 | — | — | WO | disclosed |
| US-20220204473-A1 | COMPOUND AS IRAK INHIBITOR | WUHAN CREATERNA SCIENCE AND TECHNOLOGY CO., LTD. (CN) | 2022-06-30 | — | — | US | disclosed |
| WO-2020188467-A1 | CONDENSED TRICYCLIC COMPOUND USED AS KINASE INHIBITOR | 杭州英创医药科技有限公司 | 2020-09-24 | — | — | WO | disclosed |
| EP-0746556-B1 | TRICYCLIC COMPOUNDS HAVING AFFINITY FOR THE 5-HT1A RECEPTOR | ORTHO PHARMA CORP (US) | 2002-09-25 | — | — | EP | disclosed |
| US-6376488-B1 | SPECIFIC ADRENORECEPTOR ANTAGONISTS FOR TREATING BENIGN PROSTATIC HYPERPLASIA, BLADDER OUTLET OBSTRUCTION, NEUROGENIC BLADDER, AND GYNECOLOGICAL SYNDROMES | ABBOTT LABORATORIES | 2002-04-23 | — | — | US | disclosed |
| WO-1994020497-A1 | PYRROLO-PYRIDINE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1994-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204473-A1 | COMPOUND AS IRAK INHIBITOR | IRAK1, IRAK3, IRAK2 | HTR2C 4487/4885HTR2B 4027/4885HTR2A 4420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.